Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Tianjin Pharmaceutical Da Ren Tang Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 8.30%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
STU:2TZ's 3-Year ROIIC % is ranked better than 58.18% of 947
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs STU:2TZ: 8.30
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tianjin Pharmaceutical Da Ren Tang Group 3-Year ROIIC % Related Terms
Tianjin Pharmaceutical Da Ren Tang Group 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group 3-Year ROIIC % Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group 3-Year ROIIC % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a 3-Year ROIIC % of 8.30 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 19% below median its historical median of 10.25. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #396 out of 947 companies in the Drug Manufacturers industry, placing it in the top 41.8%.
Is Tianjin Pharmaceutical Da Ren Tang Group's 3-Year ROIIC % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current 3-Year ROIIC % of 8.30 is 19% below median its 10-year median of 10.25. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. Tianjin Pharmaceutical Da Ren Tang Group's value of 8.30 is 124.3% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #396 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #396 out of 947 companies for 3-Year ROIIC %. This puts Tianjin Pharmaceutical Da Ren Tang Group in the upper half of its industry. The industry median 3-Year ROIIC % is 3.70. Tianjin Pharmaceutical Da Ren Tang Group's value of 8.30 is 124.3% above this benchmark. While the company's 10-year median is 10.25 vs. the industry median of 3.70, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current 3-Year ROIIC % of 8.30 is 124.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current 3-Year ROIIC % is 8.30, which is 19% below median its own 10-year median of 10.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.44 — trading 48.8% above its estimated fair value. The current 3-Year ROIIC % is 8.30, which is 19% below median its 10-year median of 10.25 and 124.3% above the Drug Manufacturers industry median of 3.70. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current 3-Year ROIIC % is 8.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.44 is trading 48.8% above its estimated GF Value™ of €1.64.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
3-Year ROIIC %: 8.30 (19% below median its 10-year median of 10.25)
GF Value™: €1.64 vs. price of €2.44 (48.8% above fair value)
Industry Position: 124.3% above the Drug Manufacturers median (#396 of 947)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
72GF Score
Get the complete analysis for STU:2TZ
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
